EAACI Congress 2025
BackTPS33 - Allergen immunotherapy 04
Saturday 14 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
D2.178
Allergen-specific IgE/IgG4 ratio as biomarker of allergen immunotherapy efficacy in house dust mite-sensitized allergic rhinitis
D2.169
Association of Antenatal Corticosteroid Treatment with Risk of Allergic Diseases in Children
D2.167
Effect of Metformin on allergen specific immunotherapy
D2.179
Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study
D2.180
Immunological evaluation of cat allergic individuals living with or without a cat
D2.176
Improved quality of life after PQ Grass in comparison to SLIT products in grass allergic patients
D2.174
Patient survey to determine the minimal clinically important difference for a combined symptom and medication score in grass AIT
D2.173
Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis
D2.172
Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions
D2.168
Systemic reactions to subcutaneous immunotherapy in children
D2.175
TAPAS – non-inferiority of clinical effectiveness in children compared to adults: interim results of a long-term NIS
D2.177
The Efficacy of Sublingual Immunotherapy in Mild versus Moderate Atopic Dermatitis Among Children with House Dust Mite Allergic Rhinitis
D2.171
The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment
D2.170
The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season
